Breast Cancer Research and Treatment **31**: 381, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 31

Ashley SE 73
Azzam H 357

Baum M 5,73
Baumann K 237
Benson JR 5
Berger A 337
Bernier S 217
Brenner RV 191
Brunner N 237
Bueno J 357
Buras RR 191
Byers S 203
Byers S 175,325

Chen D 153
Chen W-T 217
Chrysogelos SA 227
Clarke R 237,273
Cohen JS 285
Colletta AC 5
Cosgrove D 73
Cullen KJ 153,249

Dai M 217
Davey JB 73
Davoodi F 191
Dickson RB 153,167,301
Ding IYF 153
Dragan YP 11

Egan E 371
Ellis MJC 249
Evans SRT 191

Fahey S 11
Freter C 237
Friedl A 27

Garcia-Morales P 183
Gelmann EP 325
Glazer RI 263
Goldstein L 217
Gottardis MM 183

Hartman DP 301
Hilakivi-Clarke L 273
Honig SF 371
Hornby A 249

James M 237
Jin L 357
Johnson MD 167
Jones AL 73
Jordan VC 1,11,27,41,117,129

Kao PC 107
Kaplan O 285
Kelly T 217
Kern FG 153
Kharbanda S 153
Kiang DT 107
Kurebayashi J 153

Lauber AH 227
Lee C-C 217
Leonessa F 237
Lin C-Y 217
Lippman J 237
Lippman ME 273,301
Liu CHL 217
Liu Y 153
Lupu R 175

MacPherson A 349
Maiti SN 357
Martin MB 183
McKinna JA 73
McLeskey SW 153
Miller D 153
Monskey W 217
Morrow M 53
Mueller S 175
Mueller SC 217
Murphy JM 227
Murphy LC 61
Musgrove EA 95

Nash AG 73
Nauta RJ 191

O'Brien MER 73
Ojeifo JO 349
Olivera A 337

Paik S 153,301
Palao-Marco FL 357
Park M 203
Pitot HC 11
Powles TJ 73
Pritchard KI 83
Pulyaeva H 357

Rasmussen A 249
Rauschning W 83
Riegel AT 309
Rohlff C 263
Rowland JH 315

Saceda M 183
Sacks N 73
Schumaker LM 191
Seslar S 203
Shabahang M 191
Shi YE 167
Singer C 249
Skaar T 237
Sommers C 175,203,325
Spiegel S 337
Staebler A 175
Street K 11
Su N 349
Su Y 337
Sutherland RL 95
Swain SM 371
Sweeney KJW 95

Tamborlane JW 357
Thompson EW 175,237,325,337,357
Tidy VA 73
Tirgari R 357
Torri JA 325
Treleavan J 73

Vaughan J 11

Wapnir I 357
Warlters A 95
Watts CKW 95
Wellstein A 141,309
Winston R 107
Wolf DM 117,129

Yarden RI 227
Yeh Y 217
Yu M 357

Zhang H 337
Zhang L 153
Zhou J-Y 217
Zwiebel J 349

Breast Cancer Research and Treatment **31**: 381, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 31

Ashley SE 73
Azzam H 357

Baum M 5,73
Baumann K 237
Benson JR 5
Berger A 337
Bernier S 217
Brenner RV 191
Brunner N 237
Bueno J 357
Buras RR 191
Byers S 203
Byers S 175,325

Chen D 153
Chen W-T 217
Chrysogelos SA 227
Clarke R 237,273
Cohen JS 285
Colletta AC 5
Cosgrove D 73
Cullen KJ 153,249

Dai M 217
Davey JB 73
Davoodi F 191
Dickson RB 153,167,301
Ding IYF 153
Dragan YP 11

Egan E 371
Ellis MJC 249
Evans SRT 191

Fahey S 11
Freter C 237
Friedl A 27

Garcia-Morales P 183
Gelmann EP 325
Glazer RI 263
Goldstein L 217
Gottardis MM 183

Hartman DP 301
Hilakivi-Clarke L 273
Honig SF 371
Hornby A 249

James M 237
Jin L 357
Johnson MD 167
Jones AL 73
Jordan VC 1,11,27,41,117,129

Kao PC 107
Kaplan O 285
Kelly T 217
Kern FG 153
Kharbanda S 153
Kiang DT 107
Kurebayashi J 153

Lauber AH 227
Lee C-C 217
Leonessa F 237
Lin C-Y 217
Lippman J 237
Lippman ME 273,301
Liu CHL 217
Liu Y 153
Lupu R 175

MacPherson A 349
Maiti SN 357
Martin MB 183
McKinna JA 73
McLeskey SW 153
Miller D 153
Monskey W 217
Morrow M 53
Mueller S 175
Mueller SC 217
Murphy JM 227
Murphy LC 61
Musgrove EA 95

Nash AG 73
Nauta RJ 191

O'Brien MER 73
Ojeifo JO 349
Olivera A 337

Paik S 153,301
Palao-Marco FL 357
Park M 203
Pitot HC 11
Powles TJ 73
Pritchard KI 83
Pulyaeva H 357

Rasmussen A 249
Rauschning W 83
Riegel AT 309
Rohlff C 263
Rowland JH 315

Saceda M 183
Sacks N 73
Schumaker LM 191
Seslar S 203
Shabahang M 191
Shi YE 167
Singer C 249
Skaar T 237
Sommers C 175,203,325
Spiegel S 337
Staebler A 175
Street K 11
Su N 349
Su Y 337
Sutherland RL 95
Swain SM 371
Sweeney KJW 95

Tamborlane JW 357
Thompson EW 175,237,325,337,357
Tidy VA 73
Tirgari R 357
Torri JA 325
Treleavan J 73

Vaughan J 11

Wapnir I 357
Warlters A 95
Watts CKW 95
Wellstein A 141,309
Winston R 107
Wolf DM 117,129

Yarden RI 227
Yeh Y 217
Yu M 357

Zhang H 337
Zhang L 153
Zhou J-Y 217
Zwiebel J 349

Breast Cancer Research and Treatment **31**: 383-386, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 31

adhesion molecules
  and epithelial-mesenchymal paracrine interdependence 203-215
angiogenesis
  and epithelial-mesenchymal paracrine interdependence 203-215
  blockade of endothelial cell proliferation 141-151
  role of fibroblast growth factors 153-165
  stimulation by pleiotrophin 309-314
antiestrogens
  alternative mechanisms of action 5-9
  molecular mechanisms of action 41-52
  regulation of growth factors 61-71
  regulation of cell cycle through cyclin D1 95-105
  regulation of IGF system components 107-115
  special issue 1-138
  see also tamoxifen, droloxifene
autocrine growth factors
  see also IGFs

cadherins
  and epithelial-mesenchymal paracrine interdependence 203-215
  markers of differentiation and low invasiveness 325-335
cAMP phosphodiesterase
  inhibition as an alternative mechanism of tamoxifen 5-9
carcinogenesis
  tamoxifen as a promoter in rat liver 11-25
cell cycle
  IGFs
chemoprevention
  see prevention
cholecalciferol
  see vitamin D
collagen-I
  induces matrix metalloproteinase 2 activator in invasion 357-370
communications network
  for interactions and database sharing among SPORE investigators 377-380
cyclins
  cyclin D1 down-regulation by antiestrogens 95-105
cytokines
  blockage of tumor formation by IL-1α and IL-2 transfectants 349-356

differentiation
  and vitamin D receptor 191-202
  induced by gp30 175-182
  markers of de-differentiation and invasiveness 325-335
droloxifene
  a new antiestrogen — clinical trial 83-94
drug resistance
  *MDR*1 modulation by cAMP-dependent protein kinase inhibitors 263-271
  see also tamoxifen resistance

EGF receptor
  regulation in ER+ vs. ER– cells 227-236
endocrine therapy
  steps from ER+/EGFR– to hormone-independent ER–/EGFR+ tumors 227-236
  tamoxifen resistance and altered expression of estrogen-regulated genes 237-248
endometrial carcinoma
  possible promotion by tamoxifen 27-39
endometrium
  and growth factor regulation by antiestrogens 61-71
endothelial cell proliferation
  see angiogenesis
endothelial cells
  human umbilical vein — transfected to produce cytokines in tumor sites 349-356
epidermal growth factor
  see EGF

erbB gene family
effects on progressive tumor cell growth 153-165
erbB-2 receptor
in gp30 inhibition and differentiation of tumor cells 175-182
estrogen receptor
function and regulation of expression in breast cancer cells 183-189
in antiestrogen resistant cells 301-307
estrogen receptor
in molecular mechanisms of antiestrogen action 41-52
in tamoxifen-stimulated MCF-7 variants 117-127
point mutation in a tamoxifen-stimulated MCF-7 variant 129-138
estrogens
hormonal carcinogenesis models 237-248
extracellular matrix
degradation by proteases on invadopodia 217-226

familial cancer
and IGF-II locus 250-251
fibroblast growth factors
FGF-1 and FGF-4 transfectants and progressive growth 153-165
fibroblastic phenotype
marker of de-differentiation and invasiveness 325-335
fibroblasts
IGF production 249-263

gp30 (erbB-2 ligand)
inhibition and differentiation of tumor cells 175-182
growth factors
in therapeutic targeting of angiogenesis 141-151
see specific factors (fibroblast growth factors, heparin-binding growth factors, etc.)

heparin-binding growth factors
pleiotrophin, an angiogenesis and autocrine growth stimulator 309-314
therapeutic targeting of angiogenesis 141-151
hepatocellular carcinoma
tamoxifen as a promoter in rats 11-25
hepatocyte growth factor (HGF)
in epithelial-mesenchymal interdependence 203-215

IGF-II/mannose-6-phosphate receptor
multifunctional roles 257-258
IGFs
IGF-I and II and receptors in paracrine interactions 249-263
IGF-I regulation by tamoxifen 5-9
regulation by antiestrogens 61-71
immunotherapy
blockage of tumor formation by IL-1α and IL-2 transfectants 349-356
insulin-like growth factors
see IGFs
interleukins
blockage of tumor formation by IL-1α and IL-2 transfectants 349-356
invasion
invadopodial membrane proteases 217-226
markers of de-differentiation and invasiveness 325-335
protease MMP-2 activator induced by collagen-I gels 357-370

keratins
markers of differentiation and low invasiveness 325-335

LY-2 cells
an ER+ antiestrogen-resistant MCF-7 subline 301-307

Matrigel
tumor cell growth pattern as a de-differentiation marker 325-335
matrix degradation
proteases in breast cancer 167-173
matrix metalloproteinase 2 (MMP-2)
activator induced by collagen-I in invasive breast cancers 357-370
MCF-7 cells
characterization of tamoxifen-stimulated variants 117-127,129-138
growth factor transfection model 153-165
LY-2, an ER+ antiestrogen-resistant subline 301-307
regulation of cyclin D1 by antiestrogens 95-105

MDA-MB-435 cells
prevention of tumor formation by IL-1α or IL-2 transfection 349-356
mesenchymal condensation
and paracrine interaction with epithelial cells 203-215
met (HGF receptor)
in epithelial-mesenchymal paracrine interdependence 203-215
metabolism
techniques for NMR study 285-299
metalloproteinases
matrix-degrading proteases in breast cancer 167-173
metastasis
by FGF-1 and FGF-4 transfectants 153-165
invadopodial membrane proteases 217-226
matrix-degrading proteases in breast cancer 167-173
protease MMP-2 activator induced by collagen-I gels 357-370
multidrug resistance
*MDR*1 modulation by cAMP-dependent protein kinase inhibitors 263-271

nuclear magnetic resonance (NMR)
techniques for studies of tumor cell metabolism 285-299
nude mice
model of tamoxifen resistance and altered estrogen regulation 237-248

paracrine interactions
therapeutic targeting of angiogenesis 141-151
HGF and TGFβ in epithelial-mesenchymal interdependence 203-215
IGF-I and II roles and receptors 249-261
phosphorylation
studies by NMR techniques 285-299
platelet derived growth factor (PDGF)
sphingosine-1-phosphate as a second messenger 337-348
pleiotrophin
angiogenesis and autocrine growth stimulator 309-314
prevention
toxicity and compliance in a tamoxifen chemoprevention pilot trial 73-82
prognostic factors
invadopodial proteases and metastasis 217-226
prophylactic mastectomy
in management of very high risk women 53-60
proteases
matrix-degrading proteases in breast cancer 167-173
MMP-2 activator induced by collagen-I gels 357-370
on invadopodia, for prognosis and therapy 217-226
protein kinase C
inhibition as an alternative mechanism of tamoxifen 5-9
protein kinases
cyclic AMP dependent, and *MDR*1 modulation 263-271
psycho-oncology
SPORE research programs 315-324
pure antiestrogens
different action from tamoxifen 41-52
see also antiestrogens

quality of life
psycho-oncology research program 318-319

rats
tamoxifen as a liver carcinogen 11-25
retinoids
stimulation of pleiotrophin 309-314
risk assessment
and management of high risk women 53-60
risk factors
"cancer-prone" personality 320-321

scatter factor
see hepatocyte growth factor (HGF)
second messengers
sphingosine-1-phosphate in PDGF signal transduction 337-348
signal transduction
sphingosine-1-phosphate as a second messenger 337-348
special issues
antiestrogens 1-138
the Georgetown breast cancer SPORE 141-380
sphingosine-1-phosphate
as an intracellular second messenger 337-348

SPOREs (Specialized Programs of Research Excellence)
clinical research core facility and database 371-375
database and communications network 377-380
special issue on the Georgetown breast cancer SPORE 141-380
stromal-epithelial interactions
see paracrine interactions

tamoxifen
as a promoter of rat liver carcinogenesis 11-25
benign and malignant effects on uterus 27-39
regulation of IGF-I and TGFβ 5-9
toxicity and compliance in a chemoprevention pilot trial 73-82
tamoxifen resistance
altered expression of estrogen-regulated genes 237-248
characterization of tamoxifen-stimulated MCF-7 variants 117-127,129-138
possible molecular mechanisms 41-52
studies in ER+ LY-2 cells 301-307
transforming growth factors (TGFs)
regulation by antiestrogens 61-71
TGFβ inhibition of HGF from mesenchymal cells 203-215
TGFβ regulation by tamoxifen 5-9
transgenic immunotherapy
blockage of tumor take by IL-1α and IL-2 transfectants 349-356

uterine cancer
and growth factor regulation by antiestrogens 61-71
uterus
possible tumor promotion by tamoxifen 27-39

vimentin
markers of de-differentiation and invasiveness 325-335
vitamin D receptor
and growth inhibition 191-202
vitamin D receptor
loss with de-differentiation 191-202